Due to drug resistance, lack of cancer cell selectivity, and solubility, conventional cancer treatments lose their therapeutic uses, and as such, new therapeutic agents need to be developed. Nanomaterials and peptides are increasingly being used in the fields of cancer diagnosis, biomarker discovery due to their therapeutic values and novel way of targeting and curing the disease. Synergism among the peptide-conjugated nanoparticles is an exhilarating group of materials, not only sharing the benefits of conventional nanomedicine, but also possessing the unique properties of excellent biocompatibility, biodegradability, versatile sensitivity, specific biological purpose, and synthetic feasibility. These virtues inspired by the scientists and have taken advantage in the peptide-conjugated nano drugs for the accurate delivery of drugs reliably to the site of the lesion. This chapter offers a summary of emerging technologies that have recently been developed in the broad field of peptide-conjugated nanoparticles and offers guidance for targeted drug delivery and cancer therapy.
Engineering of hybrid anticancer drug-loaded polymeric nanoparticles delivery system for the treatment and care of lung cancer therapy
